Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05108298 · ClinicalTrials.gov registry record · NA

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

A NA study of Miscellaneous Neoplasm, NOS and Breast Cancer, NOS, sponsored by Eastern Cooperative Oncology Group.

Recruiting
Registry status
NA
Development phase
400
Enrollment target
20
Study locations

NCT05108298: Recruiting NA study of Miscellaneous Neoplasm, NOS and Breast Cancer, NOS, sponsored by Eastern Cooperative Oncology Group.

NCT05108298 is a NA study of Miscellaneous Neoplasm, NOS and Breast Cancer, NOS that is actively recruiting participants, run by Eastern Cooperative Oncology Group. The registered enrollment target is 400 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05108298, a NA study of Miscellaneous Neoplasm, NOS and Breast Cancer, NOS, is actively recruiting participants, sponsored by Eastern Cooperative Oncology Group.

RECRUITING
Registry status
NA
Development phase
400 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Primary Outcome

Will be defined as \>= 75% completed PROs at one-month. Feasibility will be compared between two arms using the two-sample proportion tests based on two binomial distributions. Fisher's exact method will be used to calculate the p value. Potential moderators will include sociodemographic information (i.e., Protocol for Responding to \& Assessing Patients' Assets, Risks \& Experiences \[PRAPARE\] form, geocoding, etc.), health literacy, adherence boosters (reminder calls, text messages), cancer t

Conditions Studied

Miscellaneous Neoplasm, NOS Breast Cancer, NOS CNS Primary Tumor, NOS Cervical Cancer, NOS Colorectal Cancer, NOS Leukemia, NOS Lymphoma, NOS Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS Testicular Nonseminomatous Germ Cell Tumor, NOS Thyroid Cancer, NOS

Interventions

  • OTHER Questionnaires

Study Locations (20)

California

  • Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
  • PCR Oncology - Arroyo Grande
  • Mercy Cancer Center - Carmichael - Carmichael
  • Mercy San Juan Medical Center - Carmichael
  • Epic Care-Dublin - Dublin
  • Mercy Cancer Center - Elk Grove - Elk Grove
  • Bay Area Breast Surgeons Inc - Emeryville
  • Epic Care Partners in Cancer Care - Emeryville
  • Contra Costa Regional Medical Center - Martinez
  • Mercy Cancer Center - Merced
  • Bay Area Tumor Institute - Oakland
  • Mercy Cancer Center - Rocklin - Rocklin
  • Mercy Cancer Center - Sacramento - Sacramento
  • Pacific Central Coast Health Center-San Luis Obispo - San Luis Obispo

Arkansas

  • Mercy Hospital Fort Smith - Fort Smith
  • CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
  • CARTI Cancer Center - Little Rock

Arizona

  • Kingman Regional Medical Center - Kingman
  • Cancer Center at Saint Joseph's - Phoenix

Alaska

  • Fairbanks Memorial Hospital - Fairbanks

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2021-11-10
Est. Completion 2027-05-01
Phase NA
Eastern Cooperative Oncology Group

141 total trials

What NCT05108298 shows while recruiting

NCT05108298 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower).

The record links to 10 conditions, with Miscellaneous Neoplasm, NOS appearing as the primary indexed condition, and to 1 intervention - of which Questionnaires is the first listed.

NCT05108298 names 20 study sites across 4 states, led by California, Arkansas, Arizona.

Frequently Asked Questions

What is clinical trial NCT05108298 about?

NCT05108298 is a clinical study titled "Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials". The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

What is the current status of trial NCT05108298?

This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2021-11-10. Estimated completion is 2027-05-01.

What conditions does trial NCT05108298 study?

This clinical trial studies the following conditions: Miscellaneous Neoplasm, NOS, Breast Cancer, NOS, CNS Primary Tumor, NOS, Cervical Cancer, NOS, Colorectal Cancer, NOS.

What interventions are being tested in trial NCT05108298?

The interventions under investigation include: Questionnaires (OTHER).

Who is sponsoring clinical trial NCT05108298?

This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05108298 being conducted?

This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Miscellaneous Neoplasm, NOS

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05108298's enrollment target sits among peer trials

400 246th of 2000 higher than 1,735 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05108298

Source: ClinicalTrials.gov NCT05108298, the US trial registry maintained by the National Library of Medicine. NCT05108298 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.